Description
Rybelsus 3mg tablet is an oral GLP-1 receptor agonist containing semaglutide, developed for adults managing type 2 diabetes or weight concerns. It works by mimicking the GLP-1 hormone to help control appetite, slow digestion, and stabilize blood glucose. The 3mg dose serves as the starting point before progressing to higher doses (7mg and 14mg).
Key Features:
-
The first oral GLP-1 treatment—no injections required
-
3mg semaglutide per tablet (starter dose)
-
Helps improve blood sugar levels and reduce appetite
-
Proven efficacy in clinical studies (NEJM research)
-
Ideal introduction to GLP-1 therapy
Usage Instructions:
-
Take one tablet daily on an empty stomach
-
Use with a small sip of water (no more than 4 oz / 120ml)
-
Wait at least 30 minutes before eating, drinking, or taking other medications
-
Begin with 3mg daily for the first 30 days before moving to 7mg as directed by your healthcare provider
Rybelsus 3mg Tablets Side Effects:
Mild effects such as nausea, abdominal discomfort, or diarrhea may occur as your body adapts. These typically decrease over time. For detailed safety information, visit the FDA Rybelsus Guide.
Storage Instructions:
-
Store at room temperature (68°F–77°F / 20°C–25°C)
-
Keep tablets in original packaging to protect from moisture and light
-
Do not refrigerate or freeze
Reviews
There are no reviews yet.